Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Clinical factors associated wi...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study

Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study

Bibliographic Details
Main Authors: Machiko Kai, Hayato Hikita, Maesaka Kazuki, Yuki Tahata, Kazuma Shinkai, Akira Doi, Kazuyoshi Ohkawa, Masanori Miyazaki, Hisashi Ishida, Kengo Matsumoto, Yasutoshi Nozaki, Takayuki Yakushijin, Ryotaro Sakamori, Akira Kaneko, Sadaharu Iio, Takatoshi Nawa, Naruyasu Kakita, Naoki Morishita, Naoki Hiramatsu, Takeo Usui, Kazuho Imanaka, Yoshinori Doi, Mitsuru Sakakibara, Yuichi Yoshida, Tsugiko Oze, Takahiro Kodama, Tomohide Tatsumi, Tetsuo Takehara
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10760712/?tool=EBI
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10760712/?tool=EBI

Similar Items

  • Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    by: Kazuki Maesaka, et al.
    Published: (2023-01-01)
  • Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
    by: Kumiko Shirai, et al.
    Published: (2022-01-01)
  • Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
    by: Naoki Morishita, et al.
    Published: (2020-01-01)
  • Evaluation of Fucosylated Haptoglobin and Mac-2 Binding Protein as Serum Biomarkers to Estimate Liver Fibrosis in Patients with Chronic Hepatitis C.
    by: Seiichi Tawara, et al.
    Published: (2016-01-01)
  • Liver Fibrosis Is Associated With Corrected QT Prolongation During Ledipasvir/Sofosbuvir Treatment for Patients With Chronic Hepatitis C
    by: Yuki Tahata, et al.
    Published: (2018-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs